Trial Profile
Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms Welcome 2
- Sponsors UCB
- 11 Jan 2017 New trial record